Search

Your search keyword '"Arestin, María"' showing total 18 results
Start Over Author "Arestin, María"
18 results on '"Arestin, María"'

2. Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer.

Author

Nemours, Stéphane, Solé, Carla, Goicoechea, Ibai, Armesto, María, Arestin, María, Urruticoechea, Ander, Rezola, Marta, López, Isabel Álvarez, Schaapveld, Roel, Schultz, Iman, Zhang, Lei, and Lawrie, Charles H. more...

Subjects
TRIPLE-negative breast cancer, BREAST cancer, MEDICAL screening, VINORELBINE, TREATMENT failure, PACLITAXEL
Abstract

Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer (BC), including as a front-line treatment for triple-negative breast cancer (TNBC) patients. However, resistance to paclitaxel remains one of the major causes of death associated with treatment failure. Multiple studies have demonstrated that miRNAs play a role in paclitaxel resistance and are associated with both disease progression and metastasis. In the present study, we used a miRNA-encoding lentiviral library as a gain-of-function screen for paclitaxel resistance in the MDA-MB-231 TNBC cell line. We identified that miR-181b, miR-29a, miR-30c, miR-196 and miR-1295 conferred a resistant phenotype to cells. The expression of miR-29a also induced resistance to eribulin and vinorelbine, while miR-181b and miR-30c induced resistance to vinorelbine. We measured the levels of these miRNAs in breast cancer patients and observed higher levels of miR-29a in treatment-refractory patients. Taken together, we suggest that miR-29a and miR-181b may be good candidates for miRNA inhibition to overcome resistance to chemotherapy. [ABSTRACT FROM AUTHOR] more...

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results

7. Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

Author

Casabonne, Delphine, Benavente, Yolanda, Seifert, Julia, Costas, Laura, Armesto, María, Arestin, María, Besson, Caroline, Hosnijeh, Fatemeh S., Duell, Eric J., Weiderpass, Elisabete, Masala, Giovanna, Kaaks, Rudolf, Canzian, Federico, Chirlaque, María Dolores, Perduca, Vittorio, Mancini, Francesca R., Pala, Valeria, Trichopoulou, Antonia, Karakatsani, Anna, La Vecchia, Carlo, Sánchez, Maria Jose, Tumino, Rosario, Gunter, Marc J., Amiano, Pilar, Panico, Salvatore, Sacerdote, Carlotta, Schmidt, Julie A., Boeing, Heiner, Schulze, Matthias B., Barricarte, Aurelio, Riboli, Elio, Olsen, Anja, Tjønneland, Anne, Vermeulen, Roel, Nieters, Alexandra, Lawrie, Charles H., de Sanjosé, Silvia, Casabonne, Delphine, Benavente, Yolanda, Seifert, Julia, Costas, Laura, Armesto, María, Arestin, María, Besson, Caroline, Hosnijeh, Fatemeh S., Duell, Eric J., Weiderpass, Elisabete, Masala, Giovanna, Kaaks, Rudolf, Canzian, Federico, Chirlaque, María Dolores, Perduca, Vittorio, Mancini, Francesca R., Pala, Valeria, Trichopoulou, Antonia, Karakatsani, Anna, La Vecchia, Carlo, Sánchez, Maria Jose, Tumino, Rosario, Gunter, Marc J., Amiano, Pilar, Panico, Salvatore, Sacerdote, Carlotta, Schmidt, Julie A., Boeing, Heiner, Schulze, Matthias B., Barricarte, Aurelio, Riboli, Elio, Olsen, Anja, Tjønneland, Anne, Vermeulen, Roel, Nieters, Alexandra, Lawrie, Charles H., and de Sanjosé, Silvia more...

Abstract

Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25–p75: 7–13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR1∆Ct-unit increase (95%CI) = 1.42 (1.18–1.72), 1.64 (1.31–2.04) and 1.75 (1.31–2.34) for hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p, respectively] and the strongest associations were observed within 10 years of diagnosis. However, the predictive performance of these miRNAs was modest (area under the curve <0.62). hsa-miR-16-5p and hsa-miR-223-3p levels were unrelated to CLL risk. The findings of this first prospective study suggest that hsa-miR-29a, hsa-miR-150-5p and hsa-miR-155-5p were upregulated in early stages of CLL but were modest predictive biomarkers of CLL risk. more...

Published
2020

8. Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

Author

IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Casabonne, Delphine, Benavente, Yolanda, Seifert, Julia, Costas, Laura, Armesto, María, Arestin, María, Besson, Caroline, Hosnijeh, Fatemeh S., Duell, Eric J., Weiderpass, Elisabete, Masala, Giovanna, Kaaks, Rudolf, Canzian, Federico, Chirlaque, María Dolores, Perduca, Vittorio, Mancini, Francesca R., Pala, Valeria, Trichopoulou, Antonia, Karakatsani, Anna, La Vecchia, Carlo, Sánchez, Maria Jose, Tumino, Rosario, Gunter, Marc J., Amiano, Pilar, Panico, Salvatore, Sacerdote, Carlotta, Schmidt, Julie A., Boeing, Heiner, Schulze, Matthias B., Barricarte, Aurelio, Riboli, Elio, Olsen, Anja, Tjønneland, Anne, Vermeulen, Roel, Nieters, Alexandra, Lawrie, Charles H., de Sanjosé, Silvia, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Casabonne, Delphine, Benavente, Yolanda, Seifert, Julia, Costas, Laura, Armesto, María, Arestin, María, Besson, Caroline, Hosnijeh, Fatemeh S., Duell, Eric J., Weiderpass, Elisabete, Masala, Giovanna, Kaaks, Rudolf, Canzian, Federico, Chirlaque, María Dolores, Perduca, Vittorio, Mancini, Francesca R., Pala, Valeria, Trichopoulou, Antonia, Karakatsani, Anna, La Vecchia, Carlo, Sánchez, Maria Jose, Tumino, Rosario, Gunter, Marc J., Amiano, Pilar, Panico, Salvatore, Sacerdote, Carlotta, Schmidt, Julie A., Boeing, Heiner, Schulze, Matthias B., Barricarte, Aurelio, Riboli, Elio, Olsen, Anja, Tjønneland, Anne, Vermeulen, Roel, Nieters, Alexandra, Lawrie, Charles H., and de Sanjosé, Silvia more...

Published
2020

9. Serum levels of hsa‐miR‐16‐5p, hsa‐miR‐29a‐3p, hsa‐miR‐150‐5p, hsa‐miR‐155‐5p and hsa‐miR‐223‐3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

Author

Casabonne, Delphine, primary, Benavente, Yolanda, additional, Seifert, Julia, additional, Costas, Laura, additional, Armesto, María, additional, Arestin, María, additional, Besson, Caroline, additional, Hosnijeh, Fatemeh S., additional, Duell, Eric J., additional, Weiderpass, Elisabete, additional, Masala, Giovanna, additional, Kaaks, Rudolf, additional, Canzian, Federico, additional, Chirlaque, María‐Dolores, additional, Perduca, Vittorio, additional, Mancini, Francesca R., additional, Pala, Valeria, additional, Trichopoulou, Antonia, additional, Karakatsani, Anna, additional, La Vecchia, Carlo, additional, Sánchez, Maria‐Jose, additional, Tumino, Rosario, additional, Gunter, Marc J., additional, Amiano, Pilar, additional, Panico, Salvatore, additional, Sacerdote, Carlotta, additional, Schmidt, Julie A., additional, Boeing, Heiner, additional, Schulze, Matthias B., additional, Barricarte, Aurelio, additional, Riboli, Elio, additional, Olsen, Anja, additional, Tjønneland, Anne, additional, Vermeulen, Roel, additional, Nieters, Alexandra, additional, Lawrie, Charles H., additional, and de Sanjosé, Silvia, additional more...

Published
2020
Full Text
View/download PDF

10. The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer

Author

Solé, Carla, primary, Goicoechea, Ibai, additional, Goñi, Alai, additional, Schramm, Maike, additional, Armesto, María, additional, Arestin, María, additional, Manterola, Lorea, additional, Tellaetxe, Maitena, additional, Alberdi, Aitor, additional, Nogueira, Leonor, additional, Roumiguie, Mathieu, additional, López, Jose Ignacio, additional, Sanz Jaka, Juan Pablo, additional, Urruticoechea, Ander, additional, Vergara, Itziar, additional, Loizaga-Iriarte, Ana, additional, Unda, Miguel, additional, Carracedo, Arkaitz, additional, Malavaud, Bernard, additional, and Lawrie, Charles H., additional more...

Published
2020
Full Text
View/download PDF

11. Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases

Author

Goicoechea, Ibai, primary, Rezola, Ricardo, additional, Arestin, María, additional, Caffarel, María M., additional, Cortazar, Ana Rosa, additional, Manterola, Lorea, additional, Fernandez-Mercado, Marta, additional, Armesto, María, additional, Sole, Carla, additional, Larrea, Erika, additional, M. Araujo, Angela, additional, Ancizar, Nerea, additional, Plazaola, Arrate, additional, Urruticoechea, Ander, additional, Carracedo, Arkaitz, additional, Ruiz, Irune, additional, Alvarez Lopez, Isabel, additional, and Lawrie, Charles H., additional more...

Published
2018
Full Text
View/download PDF

12. Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases

Author

Goicoechea, Ibai, primary, Rezola, Ricardo, additional, Arestin, María, additional, Caffarel, María M., additional, Cortazar, Ana Rosa, additional, Manterola, Lorea, additional, Fernandez-Mercado, Marta, additional, Armesto, María, additional, Sole, Carla, additional, Larrea, Erika, additional, M. Araujo, Angela, additional, Ancizar, Nerea, additional, Plazaola, Arrate, additional, Urruticoechea, Ander, additional, Carracedo, Arkaitz, additional, Ruiz, Irune, additional, Alvarez Lopez, Isabel, additional, and Lawrie, Charles H., additional more...

Published
2017
Full Text
View/download PDF

13. Aberrant Expression of MicroRNAs in B-cell Lymphomas

Author

Sole, Carla, primary, Larrea, Erika, additional, Manterola, Lorea, additional, Goicoechea, Ibai, additional, Armesto, María, additional, Arestin, María, additional, Caffarel, María, additional, Araujo, Angela, additional, Fernandez-Mercado, Marta, additional, Araiz, María, additional, and Lawrie, Charles, additional more...

Published
2016
Full Text
View/download PDF

16. Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes

Author

Lawrie, Charles H, primary, Larrea, Erika, additional, Larrinaga, Gorka, additional, Goicoechea, Ibai, additional, Arestin, María, additional, Fernandez-Mercado, Marta, additional, Hes, Ondrej, additional, Cáceres, Francisco, additional, Manterola, Lorea, additional, and López, José I, additional more...

Published
2013
Full Text
View/download PDF

18. MicroRNAs as B-cell lymphoma biomarkers.

Author

Manterola, Lorea, Fernandez-Mercado, Marta, Larrea, Erika, Goicoechea, Ibai, Arestin, María, Armesto, María, Hernandez, Luiza, and Lawrie, Charles H.

Subjects
MICRORNA, B cells, BIOMARKERS, LYMPHOMAS, ANTIGEN presenting cells
Abstract

B-cell lymphomas represent a group of more than 35 recognized mature B-cell neoplasms differentiated largely on the basis of immunohistochemical staining patterns that are often challenging to accurately diagnose. Despite having been only formally recognized just over 10 years ago, microRNAs (miRNAs) have become one of the trendiest topics in biology. Dysregulation of miRNAs is a ubiquitous feature of cancer in general, including B-cell lymphomas. Many of the miRNAs aberrantly expressed in B-cell lymphomas also play a crucial regulatory role in normal hematopoietic function. MiRNAs show great potential as novel biomarkers of cancer, as they can differentiate cancers according to diagnosis and developmental stage, even discriminating between cancers that are poorly separated histologically. Furthermore, they can be robustly measured from routinely prepared formalin-fixed paraffin-embedded biopsy material and biological fluids such as blood. Here, we consider the identity, function, and biomarker potential of miRNAs in B-cell lymphomas and, most importantly, the hurdles that remain to be overcome if they are really to become part of future clinical practice. [ABSTRACT FROM AUTHOR] more...

Published
2015
Full Text
View/download PDF